Radiation Induced Skin Fibrosis (RISF): Opportunity for Angiotensin II-Dependent Intervention.
Patricia F BootheVidya P KumarYali KongKan WangHoward LevinsonDavid MuMilton L BrownPublished in: International journal of molecular sciences (2024)
Medical procedures, such as radiation therapy, are a vital element in treating many cancers, significantly contributing to improved survival rates. However, a common long-term complication of such exposure is radiation-induced skin fibrosis (RISF), a complex condition that poses substantial physical and psychological challenges. Notably, about 50% of patients undergoing radiation therapy may achieve long-term remission, resulting in a significant number of survivors managing the aftereffects of their treatment. This article delves into the intricate relationship between RISF, reactive oxygen species (ROS), and angiotensin II (Ang II) signaling. It proposes the underlying mechanisms and examines potential treatments for mitigating skin fibrosis. The primary goal is to offer essential insights in order to better care for and improve the quality of life of cancer survivors who face the risk of developing RISF.
Keyphrases
- angiotensin ii
- radiation induced
- radiation therapy
- reactive oxygen species
- angiotensin converting enzyme
- vascular smooth muscle cells
- soft tissue
- patients undergoing
- healthcare
- wound healing
- young adults
- randomized controlled trial
- locally advanced
- palliative care
- physical activity
- mental health
- cell death
- liver fibrosis
- dna damage
- quality improvement
- pain management
- rectal cancer
- systemic lupus erythematosus
- ulcerative colitis
- sleep quality
- replacement therapy
- depressive symptoms
- smoking cessation
- combination therapy
- childhood cancer
- health insurance